deepull, a Barcelona, Spain-based medical diagnostics company, raised €50M in Series C funding.
The round was led by Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners with participation from existing investors Asabys Partners, Innvierte-CDTI, We Venture Capital, UI Investissement, Axis-ICO, Aliath Bioventures, and Kurma Partners.
The company intends to use the funds to finalize clinical validation and expedite the regulatory approval process of its UllCORE diagnostic system.
Led by CEO Jordi Carrera, deepull is a medical diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections. It is developing the UllCORE BSI Test, targeting 95% of sepsis-causing pathogens, an automated, walkaway system, which uses molecular techniques to extract and detect microbial DNA directly from whole blood. The multiplex PCR test covers 95% of sepsis-causing pathogens, including bacteria and fungi, as well as antibiotic resistance genes, providing critical results to caregivers in about one hour.
FinSMEs
30/04/2025